0001817713-20-000001.txt : 20200714 0001817713-20-000001.hdr.sgml : 20200714 20200713204643 ACCESSION NUMBER: 0001817713-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200714 DATE AS OF CHANGE: 20200713 EFFECTIVENESS DATE: 20200714 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-370889 FILM NUMBER: 201026182 BUSINESS ADDRESS: STREET 1: 11099 TORREY PINES PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92037 BUSINESS PHONE: 858-750-4700 MAIL ADDRESS: STREET 1: 11099 TORREY PINES PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92037 D 1 primary_doc.xml X0708 D LIVE 0001817713 Janux Therapeutics, Inc. 11099 TORREY PINES PARK ROAD La Jolla CA CALIFORNIA 92037 858-750-4700 DELAWARE None None Corporation true 2017 David Campbell, Ph.D. 11099 North Torrey Pines Park Road Suite 290 La Jolla CA CALIFORNIA 92037 Executive Officer Director Jay Lichter, Ph.D. 11099 North Torrey Pines Park Road Suite 290 La Jolla CA CALIFORNIA 92037 Director Stefan Heller 11099 North Torrey Pines Park Road Suite 290 La Jolla CA CALIFORNIA 92037 Director Tighe Reardon 11099 North Torrey Pines Park Road La Jolla CA CALIFORNIA 92037 Executive Officer Biotechnology Decline to Disclose 06b false 2020-06-30 false true false 0 15939220 11439224 4499996 Total Offering Amount and Total Amount Sold include amounts paid pursuant to conversion of indebtedness. false 3 0 0 0 false Janux Therapeutics, Inc. /s/ David Campbell David Campbell President and CEO 2020-07-13